NCT00749957View on ClinicalTrials.gov

Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 17, 2009

Primary Completion Date

September 23, 2014

Study Completion Date

September 22, 2017

Conditions
Leber Congenital Amaurosis
Interventions
BIOLOGICAL

rAAV2-CB-hRPE65

Recombinant adeno-associated virus vector expressing RPE65

Trial Locations (2)

97239

Casey Eye Institue, Oregon Health & Science University, Portland

01605

University of Massachusetts Medical School, Worcester

Sponsors
All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

University of Massachusetts, Worcester

OTHER

lead

Beacon Therapeutics

INDUSTRY